Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from efavirenz-containing antiretroviral therapy to Eviplera for persistent CNS toxicity
2012-002205-22Phase 3Completed
- Sponsor
- St Stephen's AIDS Trust
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of emtricitabine + rilpivirine + tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV), sponsored by St Stephen's AIDS Trust. Primary endpoint: Rate of neuropsychiatric and CNS toxicity at 12 weeks. Started Aug 2012; status: completed.
02
Drugs
emtricitabine + rilpivirine + tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2012-002205-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002205-22.